Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Change in Accured Expenses (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Change in Accured Expenses readings, the most recent being $123982.0 for Q3 2025.

  • Quarterly Change in Accured Expenses rose 148.82% to $123982.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $139209.0 through Sep 2025, up 11126.53% year-over-year, with the annual reading at $37827.0 for FY2024, 1052.58% up from the prior year.
  • Change in Accured Expenses hit $123982.0 in Q3 2025 for Greenwich LifeSciences, up from -$1510.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $123982.0 in Q3 2025 and bottomed at -$144004.0 in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $4163.8, with a median of $4940.0 recorded in 2024.
  • The largest annual shift saw Change in Accured Expenses plummeted 3313.66% in 2022 before it surged 646.74% in 2023.
  • Greenwich LifeSciences' Change in Accured Expenses stood at -$63301.0 in 2021, then skyrocketed by 139.53% to $25026.0 in 2022, then crashed by 213.07% to -$28296.0 in 2023, then soared by 129.3% to $8291.0 in 2024, then surged by 1395.38% to $123982.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Change in Accured Expenses are $123982.0 (Q3 2025), -$1510.0 (Q2 2025), and $8446.0 (Q1 2025).